Loading
Life sciences · Journal article
Obm Genetics · October 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Stem cell therapy has emerged as a transformative frontier in cancer treatment, harnessing the unique immunomodulatory capabilities of stem cells to reshape anti-tumor immune responses. Mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs), induced pluripotent stem cells (iPSCs), and cancer stem cells (CSCs) dynamically interact with innate and adaptive immune systems within the tumor microenvironment (TME). MSCs secrete cytokines such as IL-6, TGF-β, and VEGF, which exhibit context-dependent effects on cytotoxic T lymphocytes (CTLs), regulatory T cells (Tregs), and myeloid-derived suppressor cells (MDSCs). These effects vary according to factors such as MSC tissue origin, tumor type, inflammatory status, and the cytokine milieu. MSCs can also modulate tumor-associated macrophage (TAM) polarization, but the direction of polarization toward pro-tumor M2-like or anti-tumor M1-like phenotypes is highly dependent on the surrounding TME. Conversely, CSCs drive immune evasion by expressing checkpoint molecules (e.g., PD-L1) and recruiting immunosuppressive cells, illustrating stem cells’ paradoxical roles in cancer progression. Despite their promise, challenges persist: the TME’s complexity, safety concerns (tumorigenicity, immune rejection), and a lack of standardized protocols impede clinical translation. Innovations such as genetically engineered stem cells for targeted drug delivery, their potential combination with immunotherapies such as CAR-T cells and checkpoint inhibitors, and personalized approaches tailored to tumor-specific profiles offer promising experimental strategies to enhance efficacy. This review underscores stem cells’ potential role in rebalancing immune responses while emphasizing the need for further research to refine their therapeutic application. Although hematopoietic stem cell transplantation is clinically established for selected hematological malignancies, most other stem-cell-based immunomodulatory approaches remain preclinical or are under early clinical investigation.